NeoGenesis Pharmaceuticals Inc has signed a multi-year research and discovery collaboration agreement with Amgen. This collaboration will focus on the discovery of small molecule drugs aimed at certain human diseases, including cancer, neurodegenerative and inflammatory diseases.
Under the terms of this agreement, NeoGenesis will use its drug discovery technologies, including its proprietary ALIS (Automated Ligand Identification System) platform, NeoMorph compound libraries and lead optimization technologies to discover drug candidates against selected targets.
Satish Jindal, CEO and president of NeoGenesis Pharmaceuticals, Inc., said, "We are very pleased to be involved in a major research and discovery collaboration with Amgen. Amgen is well recognized for R&D innovation and the introduction of new medicines to the marketplace. We are very pleased to be able to contribute to their ongoing commitment to small molecule drugs."
Under the terms of the agreement, NeoGenesis will receive research funding, payment for achieving research and discovery milestones, and royalties based on the successful development of drug candidates.